Theravance Biopharma, Inc.
TBPH
$14.51
$0.211.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.03M | -58.33M | -56.42M | -49.40M | -45.65M |
| Total Depreciation and Amortization | 5.76M | 5.97M | 6.12M | 6.47M | 6.25M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.95M | 16.72M | 18.40M | 28.39M | 28.58M |
| Change in Net Operating Assets | 223.28M | 68.17M | 20.36M | 3.05M | 2.05M |
| Cash from Operations | 245.02M | 32.53M | -11.54M | -11.49M | -8.78M |
| Capital Expenditure | -239.00K | -241.00K | -332.00K | -819.00K | -825.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.10M | 26.13M | 12.62M | -3.26M | 14.12M |
| Cash from Investing | -7.34M | 25.89M | 12.28M | -4.08M | 13.30M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 208.00K | 627.00K | 607.00K | 617.00K | 592.00K |
| Repurchase of Common Stock | -2.30M | -2.26M | -3.10M | -33.36M | -64.37M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.09M | -1.64M | -2.50M | -32.74M | -63.77M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 235.58M | 56.78M | -1.75M | -48.31M | -59.25M |